Y Intercept Hong Kong Ltd Invests $311,000 in AnaptysBio, Inc. (NASDAQ:ANAB)

Y Intercept Hong Kong Ltd purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 23,497 shares of the biotechnology company’s stock, valued at approximately $311,000.

Several other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its position in shares of AnaptysBio by 15.3% during the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after buying an additional 438,557 shares during the period. Frazier Life Sciences Management L.P. boosted its position in shares of AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after buying an additional 43,598 shares during the period. Geode Capital Management LLC boosted its position in shares of AnaptysBio by 3.0% during the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock worth $15,594,000 after buying an additional 13,336 shares during the period. Jennison Associates LLC boosted its holdings in AnaptysBio by 1.6% in the fourth quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock valued at $3,563,000 after purchasing an additional 4,242 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock valued at $7,948,000 after purchasing an additional 206,750 shares during the period.

AnaptysBio Price Performance

AnaptysBio stock opened at $14.64 on Tuesday. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $41.31. The stock has a market cap of $445.48 million and a PE ratio of -2.41. The stock’s fifty day moving average is $16.02 and its two-hundred day moving average is $24.46.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million for the quarter, compared to analysts’ expectations of $10.17 million. On average, research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 33.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Wolfe Research assumed coverage on AnaptysBio in a report on Tuesday, February 4th. They issued an “outperform” rating and a $25.00 target price for the company. Truist Financial decreased their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of AnaptysBio in a report on Wednesday, February 12th. Finally, JPMorgan Chase & Co. decreased their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a report on Thursday, December 19th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.11.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.